OASIS Anxiety Scale: What the Overall Anxiety Severity and Impairment Scale Measures
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
The Overall Anxiety Severity and Impairment Scale, usually abbreviated OASIS, is a five-item self-report questionnaire designed to measure the overall severity and functional impact of anxiety and fear during the past week. It is transdiagnostic: instead of asking whether a person meets the symptom criteria for one named anxiety disorder, it asks how often anxiety occurs, how intense it is, how much avoidance it produces, and how much it interferes with daily and social functioning.
The scale was developed by Norman and colleagues as a brief continuous measure that could be used across anxiety disorders, with multiple co-occurring anxiety disorders, and with subthreshold anxiety symptoms. The original validation supported a single underlying dimension of anxiety-related severity and impairment. The 2006 development study included 711 college students and found evidence for test-retest reliability and convergent and divergent validity.
OASIS is useful precisely because it measures burden rather than trying to name the diagnosis. That strength also defines its limit. A total score is not a diagnosis of generalized anxiety disorder, panic disorder, social anxiety disorder, specific phobia, agoraphobia, separation anxiety disorder, or any other condition. It cannot determine whether anxiety is caused by a psychiatric disorder, a medical condition, medication, substance use, acute stress, or another context.
If the broader question is whether anxiety has crossed from a normal response into clinically significant distress or impairment, see Anxiety Disorder vs Normal Anxiety. For the larger diagnostic framework, see Anxiety Disorders: Symptoms, Types, Diagnosis, and Treatment.
What Does the OASIS Measure?
The OASIS was designed to capture clinically important dimensions that can cut across different anxiety presentations. In the large primary-care validation study, the measure showed a one-factor structure and correlated with both global and disorder-specific anxiety measures. Campbell-Sills and colleagues emphasized that the scale includes behavioral and functional consequences that many symptom checklists underrepresent.
Frequency of Anxiety and Fear
The first domain concerns how often anxiety or fear has been present during the previous week. Frequency is clinically useful because occasional anxiety and persistent anxiety can have very different meanings. Frequency alone does not establish a disorder, however. A person can experience frequent anxiety during a major life stressor, and another person can have substantial impairment while experiencing less frequent episodes because they have reorganized life around avoidance.
Intensity of Anxiety and Fear
The second domain asks about the intensity or severity of anxiety and fear when it occurs. This captures the subjective burden of the experience rather than the presence of one particular symptom such as palpitations, worry, dizziness, or muscle tension. OASIS therefore does not function as an inventory of physical or cognitive anxiety symptoms. A person can arrive at the same total score through very different symptom patterns.
Avoidance
The third domain concerns avoidance caused by anxiety or fear. This is a major feature of the scale because avoidance can hide severity. Someone who no longer enters feared situations may report fewer episodes of acute anxiety while still living with substantial restriction. Contemporary clinical characterization of anxiety conditions treats avoidance and functioning as important dimensions alongside symptom intensity. A World Psychiatry clinical review discusses the value of assessing severity, avoidance, functioning, comorbidity, and context rather than relying on diagnosis alone.
Interference With Work, School, or Home Responsibilities
The fourth domain measures how much anxiety-related difficulty interferes with major responsibilities and ordinary functioning. Functional impairment is different from symptom intensity. Two people with similar anxiety intensity can differ greatly in whether they can work, study, care for a household, travel, attend appointments, or complete necessary tasks.
Interference With Social Life and Relationships
The fifth domain focuses on social functioning and relationships. Anxiety can affect participation, communication, intimacy, family life, friendships, and ordinary social activities even when a person continues to meet work or school obligations. Including a separate social-interference domain makes the scale more sensitive to the real-life cost of anxiety than a checklist limited to internal symptoms.
For a broader map of emotional, cognitive, physical, and behavioral manifestations of anxiety, see Anxiety Symptoms. OASIS measures overall severity and impairment; it does not attempt to catalogue every possible symptom.
How Is the OASIS Scored?
Each of the five OASIS items is rated from 0 to 4, and the five responses are summed into a total score from 0 to 20. Higher totals indicate greater overall anxiety-related severity and impairment. Norman et al. (2011) described this summed total as consistent with the scale's single-factor structure and reported that the brief measure can be completed in only a few minutes.
The five questions do not all use identical verbal anchors, so the safest scoring method is to use the response options printed on the validated form rather than assuming that every item uses the same wording. The total is the primary score. The scale was not designed as five independent diagnostic subscales.
A score of 0 does not mean that a person is incapable of anxiety, and a high score does not identify which disorder is present. The number describes anxiety-related burden during the measure's time window. Interpretation depends on why the scale was administered, the population in which it is being used, the person's clinical history, and whether the purpose is screening, severity measurement, or repeated outcome monitoring.
What Does an OASIS Score of 8 Mean?
A score of 8 or higher became widely cited as a screening threshold because an early primary-care validation study found that this cutoff correctly classified 87% of its referred sample, with 89% sensitivity and 71% specificity. That 2009 validation study supported the usefulness of OASIS as a screening and assessment tool in that setting.
A later nonclinical college study also found 8 to be the most efficient cutoff in its small diagnostic subsample, but performance differed: sensitivity was 69% and specificity was 74%. The authors explicitly noted that other cutoffs can be chosen depending on whether the goal is greater sensitivity or greater specificity and that additional populations might produce different optimal thresholds. Those data are reported in Norman et al. (2011).
The most important update is the 2026 systematic review and multiple-threshold meta-analysis. It included four diagnostic-accuracy studies with 736 adults, all of whom had specific chronic somatic conditions. At the commonly recommended cutoff of 8, pooled sensitivity was 0.44 and specificity 0.89 for any anxiety disorder; for generalized anxiety disorder, pooled sensitivity was 0.58 and specificity 0.87. The Youden-index optimum was lower—5 for any anxiety disorder and 6 for GAD—but the authors stressed that the evidence base was small and restricted to somatic-disease populations. They concluded that the recommended cutoff needs reconsideration. See Fomenko et al. (2026).
The practical conclusion is that 8 should be treated as a historically well-supported research cutoff, not as a universal diagnostic boundary. It can be useful in some settings, but a score below 8 does not rule out an anxiety disorder, and a score of 8 or above does not establish one. The threshold's meaning changes with the population, prevalence of anxiety disorders, purpose of testing, and the relative cost of false-positive and false-negative results.
Are There Mild, Moderate, and Severe OASIS Score Ranges?
Some studies have proposed severity anchors, but they should not be presented as universal clinical bands. In a psychiatric outpatient sample of 202 people, Bragdon and colleagues compared OASIS scores with the clinician-rated Clinical Global Impression-Severity scale and reported OASIS values of approximately 6, 10, and 12 corresponding to moderate, marked, and severe illness in that sample.
Other populations have produced different thresholds. A large Czech standardization study, for example, derived a clinical/nonclinical cutoff around 6 and proposed sample-specific severity ranges that differ from the psychiatric outpatient anchors. Mikoska et al. (2022) therefore provides useful evidence that score interpretation can shift across samples, languages, and validation methods.
For an individual reader, the scientifically defensible interpretation is continuous: higher OASIS totals generally indicate greater anxiety-related severity and impairment. Labels such as mild, moderate, or severe should be used only when a validated scoring framework for the relevant population and purpose supports them.
OASIS Is a Severity and Impairment Measure, Not a Diagnosis
This distinction is central. The American Psychiatric Association states that assessment measures should enhance clinical decision-making rather than serve as the sole basis for a clinical diagnosis. APA's DSM-5-TR assessment guidance makes that principle explicit.
OASIS does not test the full diagnostic criteria for generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder, specific phobia, separation anxiety disorder, or selective mutism. It does not establish symptom duration requirements, developmental appropriateness, exclusion criteria, substance or medication effects, medical causes, or the detailed fear pattern that distinguishes one disorder from another.
It also does not make obsessive-compulsive disorder, post-traumatic stress disorder, illness anxiety disorder, attachment anxiety, or neuroticism into anxiety-disorder subtypes. A person with one of those conditions can experience substantial anxiety and therefore obtain an elevated OASIS score, but the score does not change the diagnostic classification of the underlying condition.
The same logic applies to screening generally. The U.S. Preventive Services Task Force notes that people who screen positive for anxiety need further evaluation for diagnosis and, when appropriate, evidence-based care. USPSTF's 2023 recommendation separates the screening step from confirmatory diagnostic assessment.
What Can a High OASIS Score Reflect?
A high OASIS total means that the person is reporting a substantial combination of anxiety frequency, anxiety intensity, avoidance, and interference. It does not identify the cause. The same score could occur in generalized anxiety disorder, panic disorder, social anxiety disorder, agoraphobia, a specific phobia, another psychiatric condition with prominent anxiety, a period of severe situational stress, or a medical or substance-related state.
Clinical interpretation therefore asks what is producing the score. Relevant questions include whether anxiety is tied to persistent generalized worry, unexpected panic attacks, social scrutiny, a specific object or situation, separation, trauma reminders, obsessions, health concerns, medication changes, stimulant or other substance use, sleep deprivation, endocrine or cardiovascular problems, respiratory symptoms, or another medical condition.
OASIS should not be used to explain chest pain, palpitations, shortness of breath, fainting, new neurologic symptoms, or other potentially significant physical symptoms as anxiety simply because a score is elevated. A questionnaire cannot safely distinguish panic from arrhythmia, asthma, seizure, endocrine disease, medication effects, or other medical causes when symptoms overlap. New, severe, atypical, or unexplained physical symptoms require appropriate medical assessment.
For the distinction between symptoms, screening results, and clinical disorder, Is Anxiety a Mental Illness? explains why anxiety as an experience is broader than any formal diagnosis.
What Can a Low OASIS Score Mean?
A low total usually indicates relatively low anxiety-related severity and impairment during the past week, but it is not a certificate of absence. Timing matters: symptoms may fluctuate, and a calm week can follow a difficult one. Avoidance matters too. Someone who has successfully eliminated nearly all exposure to a feared situation may report fewer episodes of acute anxiety while still having a clinically important pattern of restriction.
Because OASIS includes an avoidance item, it is better positioned than a pure symptom-frequency checklist to detect some of this hidden burden. Even so, no five-item self-report scale can reconstruct a complete clinical history. A person can also underreport, misunderstand response options, interpret the time frame differently, or have impairment driven by a condition not well captured by OASIS.
Can OASIS Be Used to Track Treatment or Change Over Time?
Yes. Repeated administration is one of the most defensible uses of a brief continuous severity measure. When the same person completes OASIS at consistent intervals, clinicians and researchers can examine whether the overall burden of anxiety, avoidance, and interference is moving up, down, or remaining stable.
In a specialty anxiety-treatment sample, Moore et al. (2015) found that change in OASIS scores tracked change on other measures and estimated that a four-point change could be considered statistically reliable in that sample. Later research has also used a four-point criterion for reliable change, but the estimate should not be converted into a universal rule for every population, language, clinical setting, or individual.
A lower score after treatment can indicate improvement in overall anxiety-related burden, yet remission from a specific disorder requires more than a total-score drop. Disorder-specific symptoms, avoidance patterns, functioning, adverse effects, patient goals, and diagnostic criteria may still need direct assessment. A person can improve meaningfully without crossing a particular cutoff, and another person can cross a cutoff while important problems remain.
OASIS vs GAD-7
OASIS and the GAD-7 overlap in that both are short self-report tools used in anxiety assessment, but they were built for different purposes. GAD-7 was developed around symptoms of generalized anxiety disorder and is often used as a GAD-focused screener and symptom-severity measure. OASIS is shorter and deliberately transdiagnostic: it asks about overall anxiety or fear, avoidance, and functional interference without requiring the person to fit one specific anxiety-disorder symptom pattern.
That makes OASIS useful when the clinical question is, “How much anxiety-related burden is present overall?” It makes GAD-7 more directly aligned with the question, “How prominent are core generalized-anxiety symptoms?” Neither questionnaire alone identifies the full differential diagnosis, and neither score should be turned into a formal diagnosis without assessment.
For a person with panic disorder, specific phobia, or social anxiety disorder, OASIS may better capture broad severity across frequency, intensity, avoidance, and impairment than a GAD-focused scale. For a person being specifically evaluated for generalized anxiety disorder, a GAD-focused instrument can contribute different information. In clinical practice, the instrument should be chosen because it matches the assessment question, not because one scale is universally superior.
OASIS vs Beck Anxiety Inventory and Hamilton Anxiety Rating Scale
The Beck Anxiety Inventory, Hamilton Anxiety Rating Scale, and OASIS are also not interchangeable. The Beck Anxiety Inventory emphasizes a range of anxiety symptoms, many of them somatic. The Hamilton Anxiety Rating Scale is a clinician-rated measure developed to rate anxiety severity across psychic and somatic domains. OASIS is a five-item self-report measure centered on frequency, intensity, avoidance, and functional interference.
These differences matter when physical illness can mimic or amplify anxiety symptoms. A measure that weights somatic symptoms heavily can behave differently in medical populations from a measure that explicitly includes avoidance and impairment. Choice of instrument should therefore consider population, clinical purpose, mode of administration, and what construct the score is intended to represent.
Psychometric Evidence for the OASIS
Established Evidence
Across multiple studies, the most consistent finding is that OASIS behaves as a largely unidimensional measure of overall anxiety-related severity and impairment. The original development study, the large primary-care validation, the nonclinical follow-up, and psychiatric outpatient studies all reported evidence supporting a total score rather than separate diagnostic subscales. Norman et al. (2006), Campbell-Sills et al. (2009), and Bragdon et al. (2016) provide converging evidence across different clinical contexts.
The measure's brevity and transdiagnostic design are also well supported. It can capture anxiety-related burden even when a person has multiple anxiety diagnoses or symptoms that do not map neatly onto a single disorder. That property is especially useful for outcome monitoring and settings in which a longer disorder-by-disorder battery is impractical.
Evidence That Requires Context
Cutoff scores require much more caution than the existence of the scale itself. The historically common threshold of 8 performed well in several older samples, yet diagnostic performance varies by setting. The 2026 meta-analysis found substantially lower sensitivity at 8 in adults with chronic somatic disease and explicitly called for reconsideration of the recommended threshold. The evidence therefore supports OASIS as a measure more strongly than it supports one universal cutoff.
Severity bands and reliable-change thresholds are similarly context-dependent. Psychiatric outpatient, specialty-treatment, primary-care, and population samples do not produce identical interpretations. A numeric rule derived from one validation study should not be silently generalized to a different language, age group, medical population, or clinical purpose.
Cross-Language and Cross-Cultural Evidence
OASIS has been studied in translated versions, including Spanish, Czech, and German adaptations. A Spanish online validation in 583 patients with emotional disorders supported use of an online transdiagnostic version, while Czech and German studies found generally favorable psychometric properties but different optimal cutoffs in their samples. The Spanish validation and the Czech standardization illustrate why translation and population validation matter.
Cross-language evidence strengthens confidence that the underlying construct can be measured beyond one English-speaking sample, but it does not justify assuming measurement equivalence or identical cutoffs everywhere. Clinical services should use validated versions and locally appropriate interpretation guidance when available.
Can Children and Adolescents Use the OASIS?
Most of the foundational OASIS evidence concerns adults or college-aged participants. Youth assessment has therefore required separate study rather than automatic transfer of adult norms. A caregiver-report adaptation, OASIS-Y, has been psychometrically evaluated for youth populations. Comer and colleagues' study supports the broader principle that developmental adaptations need their own evidence.
For children and adolescents, the choice of anxiety measure should consider age, developmental level, informant, school and family context, and the specific disorder being assessed. An adult OASIS cutoff should not simply be imported into pediatric decision-making.
How Clinicians and Researchers Can Use OASIS Responsibly
OASIS is most informative when its role is explicit. As a screening measure, it can flag that anxiety-related burden may warrant fuller assessment. As a severity measure, it can summarize overall burden at a point in time. As an outcome measure, it can track change across repeated administrations. These are related uses, but they are not the same clinical question.
A responsible interpretation combines the total score with the person's own account of what changed. A falling score may reflect lower anxiety intensity, less avoidance, better functioning, or several of these together. A stable total can hide improvement in one domain and deterioration in another. Looking at the response pattern as well as the total can therefore help clinical conversation even though the validated scoring model is primarily a summed score.
Context should also include treatment stage, medication changes, acute stressors, substance use, sleep, medical illness, and major environmental changes. A questionnaire is a structured snapshot. Its value comes from making one part of the clinical picture measurable, not from replacing the rest of the picture.
Common Misinterpretations of the OASIS
“A Score of 8 Means I Have an Anxiety Disorder”
It does not. Eight is a screening threshold supported by several older validation samples, and its diagnostic accuracy is not constant across populations. A formal diagnosis requires assessment of the actual disorder criteria, duration, impairment, exclusions, differential diagnoses, medical context, and clinical history.
“A Score Below 8 Means I Do Not Have an Anxiety Disorder”
It does not. Screening tests can miss true cases, and the latest meta-analysis found limited sensitivity for the cutoff of 8 in the available chronic-somatic-disease studies. Symptoms can also fluctuate across weeks or be reduced by extensive avoidance.
“OASIS Is a Test for Generalized Anxiety Disorder”
OASIS is transdiagnostic. It can be elevated in generalized anxiety disorder, but it was deliberately designed to assess severity and impairment across anxiety presentations. It does not test the full GAD criteria or distinguish GAD from other anxiety disorders.
“The Total Score Tells Me Which Treatment I Need”
It does not. Treatment selection depends on the diagnosis or problem formulation, symptom pattern, medical history, comorbidity, age, preferences, previous treatment response, access, risks, and goals. OASIS can help monitor burden; it cannot prescribe a disorder-specific treatment plan.
“A Four-Point Drop Always Means Remission”
No. A four-point change has been estimated as reliable in some treatment samples, but reliable change and remission are different concepts. Remission requires an appropriate clinical definition and may include disorder-specific symptoms, functioning, and diagnostic status beyond the OASIS total.
When Should an OASIS Result Lead to Further Assessment?
Further assessment is reasonable when anxiety or fear is persistent, worsening, difficult to control, producing substantial avoidance, or interfering with work, school, relationships, sleep, mobility, health care, or ordinary responsibilities. An elevated OASIS score can support that decision, but impairment and clinical concern matter even when the score falls below a conventional threshold.
Assessment is also important when the anxiety pattern is new or unusual, when symptoms began after a medication or substance change, when depression, trauma symptoms, obsessive-compulsive symptoms, psychosis, mania, or substance-related problems may be present, or when physical symptoms could reflect a medical condition. The goal is to understand what is happening, not simply to attach a label to a number.
Urgent medical evaluation is appropriate for potentially serious physical symptoms such as new or severe chest pain, severe breathing difficulty, fainting, sudden neurologic deficits, or other acute symptoms that could reflect a medical emergency. OASIS has no role in ruling those conditions out.
Frequently Asked Questions
What does OASIS stand for?
OASIS stands for Overall Anxiety Severity and Impairment Scale. It is a five-item self-report measure of overall anxiety- and fear-related severity, avoidance, and functional impairment.
How many questions are on the OASIS?
There are five items. Each is scored from 0 to 4, creating a total from 0 to 20.
What time period does OASIS cover?
The standard OASIS asks respondents to consider anxiety and fear during the past week. That short window makes it useful for repeated measurement, but it also means scores can change when a person's week changes.
Is OASIS a screening test or a severity scale?
It can serve both functions, depending on how it is used. The instrument measures severity and impairment continuously, and studies have also evaluated cutoff scores for screening. Screening interpretation requires population-specific caution, especially in light of the 2026 diagnostic-accuracy meta-analysis.
Does an OASIS score diagnose an anxiety disorder?
No. It is a questionnaire score, not a formal diagnosis. Diagnosis requires clinical assessment and disorder-specific criteria.
What is the cutoff for OASIS?
A total of 8 or higher is the historically common cutoff from several validation studies, but it should not be treated as universal. The latest meta-analysis found that performance at 8 varied substantially and that lower thresholds maximized the statistical balance of sensitivity and specificity in the limited somatic-disease evidence base.
Can OASIS be used during treatment?
Yes. Repeated scores can help track overall change in anxiety-related severity and impairment. Some studies estimate that a four-point change can be statistically reliable, but that value is not a universal definition of recovery or remission.
Is OASIS only for generalized anxiety disorder?
No. OASIS was developed as a transdiagnostic measure that can be used across anxiety disorders, with multiple co-occurring anxiety disorders, and with subthreshold anxiety symptoms.
Why does OASIS include avoidance and impairment?
Because symptom frequency and intensity alone can underestimate how much anxiety shapes a person's life. Avoidance may reduce immediate anxiety while increasing restriction, and functional impairment captures consequences that symptom checklists can miss.
Related Articles
References
American Psychiatric Association. DSM-5-TR Online Assessment Measures. Psychiatry.org.
Bragdon, L. B., Diefenbach, G. J., Hannan, S., & Tolin, D. F. (2016). Psychometric properties of the Overall Anxiety Severity and Impairment Scale (OASIS) among psychiatric outpatients. Journal of Affective Disorders, 201, 112–115. https://doi.org/10.1016/j.jad.2016.05.005
Campbell-Sills, L., Norman, S. B., Craske, M. G., Sullivan, G., Lang, A. J., Chavira, D. A., Bystritsky, A., Sherbourne, C., Roy-Byrne, P., & Stein, M. B. (2009). Validation of a brief measure of anxiety-related severity and impairment: The Overall Anxiety Severity and Impairment Scale (OASIS). Journal of Affective Disorders, 112(1–3), 92–101. https://doi.org/10.1016/j.jad.2008.03.014
Comer, J. S., Conroy, K., Cornacchio, D., et al. (2022). Psychometric evaluation of a caregiver-report adaptation of the Overall Anxiety Severity and Impairment Scale (OASIS) for use with youth populations. Journal of Affective Disorders, 300, 341–348. https://doi.org/10.1016/j.jad.2021.12.113
Fomenko, A., Marrie, R. A., Dümmler, D., et al. (2026). Test accuracy of the Overall Anxiety Severity and Impairment Scale (OASIS) for screening anxiety in adults: Systematic review and multiple thresholds meta-analysis. Journal of Affective Disorders, 400, 121126. https://doi.org/10.1016/j.jad.2025.121126
González-Robles, A., Mira, A., Miguel, C., et al. (2018). A brief online transdiagnostic measure: Psychometric properties of the Overall Anxiety Severity and Impairment Scale (OASIS) among Spanish patients with emotional disorders. PLOS ONE, 13(11), e0206516. https://doi.org/10.1371/journal.pone.0206516
Mikoska, P., Novak, L., Pilarik, L., Bok, T., Fulep, M., & Korinek, R. (2022). A Czech version of the Overall Anxiety Severity and Impairment Scale (OASIS): Standardization and psychometric properties. BMC Psychiatry, 22, 822. https://doi.org/10.1186/s12888-022-04365-5
Moore, S. A., Welch, S. S., Michonski, J., Poquiz, J., Osborne, T. L., Sayrs, J., & Spanos, A. (2015). Psychometric evaluation of the Overall Anxiety Severity and Impairment Scale (OASIS) in individuals seeking outpatient specialty treatment for anxiety-related disorders. Journal of Affective Disorders, 175, 463–470. https://doi.org/10.1016/j.jad.2015.01.041
Norman, S. B., Campbell-Sills, L., Hitchcock, C. A., Sullivan, S., Rochlin, A., Wilkins, K. C., & Stein, M. B. (2011). Psychometrics of a brief measure of anxiety to detect severity and impairment: The Overall Anxiety Severity and Impairment Scale (OASIS). Journal of Psychiatric Research, 45(2), 262–268. https://doi.org/10.1016/j.jpsychires.2010.06.011
Norman, S. B., Hami Cissell, S., Means-Christensen, A. J., & Stein, M. B. (2006). Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS). Depression and Anxiety, 23(4), 245–249. https://doi.org/10.1002/da.20182
Stein, D. J., Craske, M. G., Rothbaum, B. O., et al. (2021). The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. World Psychiatry, 20(3), 336–356. https://doi.org/10.1002/wps.20919
U.S. Preventive Services Task Force. (2023). Anxiety Disorders in Adults: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening